{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:33:17Z","timestamp":1755225197291,"version":"3.43.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Calcimimetics are a group of medications that increase the sensitivity of the calcium receptors to extracellular calcium ions and inhibit the release of parathyroid hormone (PTH) in patients with chronic kidney disease (CKD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to analyze the global trends in the publication of articles on calcimimetics through bibliometric analysis of the Web of Science and Scopus databases, as well as to identify the most highly cited articles from 1997 to 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Systematic and thematic analyses were performed to provide substantial insights into calcimimetic research. Data were analyzed using VOS viewer (var1.6.6) and the Biblioshiny tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,500 documents were identified for analysis. There was an exponential growth in calcimimetic-associated publications (from 57 documents in 2004 to 258 in 2021). The mean of the total citations per article showed a decrease from 226 in 1998 to 0 in 2024. The United States was the most productive country. Goodman W. emerged as the most prolific author, with high-level metrics [<jats:italic>n<\/jats:italic> = 45, total number of citations (TNC) = 4,768, <jats:italic>h<\/jats:italic>_index = 27]. Fukazawa M. showed the longest research activity in the field, with 97 published documents in 25 years. Nephrology Dialysis Transplantation was the most published journal, with 112 documents and with an <jats:italic>h<\/jats:italic>_index of 43. The thematic KeyWords Plus analysis identified three key domains, including pharmacological targets (CaSR and cinacalcet) reported in niche themes and central CKD and mineral bone disorder (MBD) pathway (hemodialysis, vascular calcification, and vitamin D) case reports in emerging\/declining themes. The small correlation between \u201cdiabetes\u201d and \u201cmineral metabolism\u201d (despite shared CKD complications) suggests a critical research gap. While our thematic map highlighted robust research on the pathophysiology of CKD-MBD, critical clinical outcomes remain underexplored. Future trials should highlight these gaps, particularly in high-risk subgroups such as diabetic patients with CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of this review offer a summary of the global landscape, the key research areas, and possible future directions in calcimimetic research. This information can assist researchers in exploring the knowledge structure and understanding future trends in calcimimetic research, as well as in supporting collaboration toward advanced global research on calcimimetics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneph.2025.1617466","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T07:05:56Z","timestamp":1755068756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring global calcimimetics research trends: a systematic and thematic review of Web of Science and Scopus databases from 1997 to 2024"],"prefix":"10.3389","volume":"5","author":[{"given":"Riad","family":"Abdelrahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha H.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiamaka Linda","family":"Mgbechidinma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eltieb Omer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","year":"2024","DOI":"10.1016\/S0085-2538(24)00110-8"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012223","article-title":"Mineral bone disorders in kidney disease patients: the ever-current topic","volume":"23","author":"Hu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B3","unstructured":"Applied Therapeutics (Koda Kimble and Youngs Applied Therapeutics)\n          \n          \n            \n              Zeind\n              CS\n            \n            \n              Carvalho\n              MG\n            \n          \n          Philadelphia\n          Wolters Kluwer\n          Professional & Technical Kindle eBooks\n          \n          2023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-112","article-title":"Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study","volume":"14","author":"Kim","year":"2013","journal-title":"BMC Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/mjt.0b013e318145a6ba","article-title":"Pharmacotherapy: A pathophysiologic approach","author":"Somberg","year":"2007","journal-title":"Am J Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B7","first-page":"1927","article-title":"Chronic kidney disease","volume":"12","author":"Hudson","year":"2023","journal-title":"Pharmacotherapy: A Pathophysiologic Approach"},{"key":"B8","unstructured":"List of Calcimimetics\n          \n          \n          Drugs.com\n          \n          2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/B978-0-12-801238-3.11267-X","article-title":"Calcimimetics for treating hyperparathyroidism","volume":"3","author":"Wada","year":"2020","journal-title":"Encycl Bone Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2362.2007.01874.X","article-title":"The role of calcimimetics in the treatment of hyperparathyroidism","volume":"37","author":"W\u00fcthrich","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/S00423-019-01755-4","article-title":"Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis","volume":"404","author":"Dulfer","year":"2019","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEFROE.2017.10.008","article-title":"Calcimimetics have had no impact on the indications for surgery of tertiary hyperparathyroidism","volume":"37","author":"Ruiz","year":"2017","journal-title":"Nefrol (English Ed"},{"key":"B13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/B978-0-323-66127-0.00061-2","article-title":"Surgical management of secondary and tertiary hyperparathyroidism","author":"Tominaga","year":"2021","journal-title":"Surg Thyroid Parathyr Gland"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1245\/S10434-016-5450-6\/TABLES\/3","article-title":"Impact of the introduction of calcimimetics on timing of parathyroidectomy in secondary and tertiary hyperparathyroidism","volume":"24","author":"van der Plas","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304649","article-title":"The\u00a0impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data","volume":"19","author":"Disthabanchong Id","year":"2024","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"B17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2217\/cer-2018-0015","article-title":"Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis","volume":"7","author":"Lozano-Ortega","year":"2018","journal-title":"J Comp Eff Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41598-018-21397-8","article-title":"Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2018.10.021","article-title":"Pharmacology of Parsabiv\u00ae (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients","volume":"842","author":"Harada","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-008055232-3.63963-7","article-title":"Cinacalcet","volume":"1","author":"Junaid","year":"2024","journal-title":"xPharm Compr Pharmacol Ref"},{"key":"B21","volume-title":"Applied Therapeutics: The Clinical\u00a0Use Of Drugs","author":"Koda-Kimble","year":"2008"},{"key":"B22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/J.1476-5381.2011.01317.X","article-title":"The calcium-sensing receptor and calcimimetics in blood pressure modulation","volume":"164","author":"Smajilovic","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.06.022","article-title":"Evocalcet in the management of secondary hyperparathyroidism in dialysis patients","volume":"94","author":"Parfrey","year":"2018","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/17446651.2020.1780911","article-title":"Development of evocalcet for unmet needs among calcimimetic agents","volume":"15","author":"Hamano","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1124\/MOLPHARM.122.000522","article-title":"Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor","volume":"102","author":"Sato","year":"2022","journal-title":"Mol Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-021-01578-Y","article-title":"Upacicalcet: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0301954","article-title":"Prevalence of chronic kidney disease among young people living with HIV in Sub Saharan Africa: A systematic review and meta-analysis","volume":"19","author":"Nasuuna Id","year":"2024","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2023.1123582\/BIBTEX","article-title":"Global trends\u00a0and\u00a0research frontiers on heat stress in poultry from 2000 to 2021: A bibliometric analysis","volume":"14","author":"Uyanga","year":"2023","journal-title":"Front Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/S13596-022-00670-2","article-title":"Traditional herbal medicine: overview of research indexed in the scopus database","volume":"23","author":"Musa","year":"2022","journal-title":"Adv Tradit Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ASI.24881","article-title":"Which international co-authorships produce higher quality journal articles","volume":"75","author":"Thelwall","year":"2024","journal-title":"J Assoc Inf Sci Technol"},{"key":"B31","first-page":"1","article-title":"The Geography of Scientific Collaboration","author":"Olechnicka","year":"2018"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin Kidney J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The evaluation of cinacalcet hcl therapy to lower cardiovascular events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2017.05.002","article-title":"Mortality in dialysis patients with cinacalcet use: A large observational registry study","volume":"42","author":"Friedl","year":"2017","journal-title":"Eur J Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2023.1146955\/BIBTEX","article-title":"Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1617466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T07:05:58Z","timestamp":1755068758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1617466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":37,"alternative-id":["10.3389\/fneph.2025.1617466"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1617466","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1617466"}}